san carlos
-
Ambagon adds $85M for molecular glues that stick to elusive protein targets
Biotech startup Ambagon Therapeutics is taking a new approach to making elusive protein targets “druggable” by using molecular glues. The biotech has a pipeline of preclinical cancer drugs and it has raised $85 million to support their development.
-
Artificial Intelligence, BioPharma
Engine Biosciences revs up $43M for AI tech that yields targeted cancer therapies
Engine Biosciences closed a $43 million Series A financing that the startup will apply to its artificial intelligence-based technology for drug discovery. The company analyzes genetic interactions, “deciphering biology” to find new cancer drugs.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Iovance could use ongoing Phase II trial to support FDA approval for cell therapy
The company said the agency told it that it may consider data from an amended version of the trial of LN-145 for approval. An analyst wrote that approval could happen in the first half of 2021, based on Iovance’s guidance for regulatory submission.